Skip to main content
. 2022 Oct;10(20):1091. doi: 10.21037/atm-22-1353

Table 1. Baseline characteristics in patients with HCC undergoing liver transplantation.

Variable Items All patients (n=242) Patients beyond Milan criteria (n=140)
Control (n=200) Lenvatinib (n=42) P value Control (n=102) Lenvatinib (n=38) P value
Gender Male 173 (86.5) 40 (95.2) 0.113 90 (88.2) 36 (94.7) 0.410a
Female 27 (13.5) 2 (4.8) 12 (11.8) 2 (5.3)
Age (years) ≤50 99 (49.5) 21 (50.0) 0.953 49 (48.0) 20 (52.6) 0.629
>50 101 (50.5) 21 (50.0) 53 (52.0) 18 (47.4)
HBsAg Negative 39 (19.5) 11 (26.2) 0.330 19 (18.6) 10 (26.3) 0.318
Positive 161 (80.5) 31 (73.8) 83 (81.4) 28 (73.7)
AFP (ng/mL) ≤400 161 (80.5) 34 (81.0) 0.946 76 (74.5) 31 (81.6) 0.381
>400 39 (19.5) 8 (19.0) 26 (25.5) 7 (18.4)
PIVKA-II (mAU/mL) <100 104 (52.0) 12 (28.6) 0.006 39 (38.2) 10 (26.3) 0.189
>100 96 (48.0) 30 (71.4) 63 (61.8) 28 (73.7)
Child-Pugh class A 128 (64.0) 33 (78.6) 0.069 69 (67.6) 30 (78.9) 0.191
B-C 72 (36.0) 9 (21.4) 33 (32.4) 8 (21.1)
Cirrhosis No 32 (16.0) 7 (16.7) 0.915 23 (22.5) 7 (18.4) 0.597
Yes 168 (84.0) 35 (83.3) 79 (77.5) 31 (81.6)
Tumor size (cm) ≤5 159 (79.5) 24 (57.1) 0.002 61 (59.8) 20 (52.6) 0.445
>5 41 (20.5) 18 (42.9) 41 (40.2) 18 (47.4)
Tumor number Single 74 (37.0) 9 (21.4) 0.053 9 (8.8) 6 (15.8) 0.380a
Multiple 126 (63.0) 33 (78.6) 93 (91.2) 32 (84.2)
Edmondson stage I-II 111 (55.5) 20 (47.6) 0.351 51 (50.0) 18 (47.4) 0.782
III-IV 89 (44.5) 22 (52.4) 51 (50.0) 20 (52.6)
mVI No 96 (48.0) 16 (38.1) 0.242 39 (38.2) 14 (36.8) 0.880
Yes 104 (52.0) 26 (61.9) 63 (61.8) 24 (63.2)
CNLC stage I 107 (53.5) 10 (23.8) <0.001 9 (8.8) 6 (15.8) 0.380a
II 93 (46.5) 32 (76.2) 93 (91.2) 32 (84.2)
Milan criteria Within 98 (49.0) 4 (9.5) <0.001 0 0 /
Beyond 102 (51.0) 38 (90.5) 102 (100.0) 38 (100.0)
Fudan criteria Within 124 (62.0) 11 (26.2) <0.001 26 (25.5) 7 (18.4) 0.381
Beyond 76 (38.0) 31 (73.8) 76 (74.5) 31 (81.6)
Preoperative TACE No 134 (67.0) 24 (57.1) 0.222 55 (53.9) 22 (57.9) 0.674
Yes 66 (33.0) 18 (42.9) 47 (46.1) 16 (42.1)
Duration of surgery (minutes) 308.0
[278.0, 332.0]
308.0
[272.0, 329.3]
0.563 308.00
[284.0, 332.0]
305.0
[272.0, 330.0]
0.431b
Blood loss (mL) 800.0
[400.0, 1,500.0]
800.0
[600.0, 1,175.0]
0.433 900.0
[500.0, 1,500.0]
800.0
[600.0, 1,200.0]
0.82b
Warm ischemic time (minutes) 40.0
[36.0, 44.0]
40.0
[36.0, 45.0]
0.822 40.0
[36.3, 44.0]
39.5
[36.0, 45.0]
0.365b

Categorical variables were summarized as n (%); continuous variables were summarized as median [interquartile range]. a, continuous correction. b, Wilcoxon rank-sum test. AFP, alpha-fetoprotein; CNLC, China Liver Cancer Stage; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; mVI, microvascular invasion; PIVKA-II, protein induced by vitamin K absence or antagonist-II; TACE, transarterial chemoembolization.